Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2005
12/01/2005US20050267012 Contacting with Bacillus anthracis lethal factor
12/01/2005US20050267011 Calcium channel modulators; inhibiting neurogenesis; N-methyl-D-asparate (NMDA) receptors
12/01/2005US20050267010 using an in-dwelling bilateral local renal delivery catheter that is adapted to maintain the position of a bilateral local renal injection assembly at an injection location associated with the renal arteries; delivering A, B or C-type natriuretic peptide; dyspnea; chronic renal insufficiency, diabetes
12/01/2005US20050267009 Method of Treatment of Acute and Persistent Pain
12/01/2005US20050266533 Therapeutic fusion protein with enhanced for use in prevention and treatment of cell proliferative, blood and nervous system disorders
12/01/2005US20050266532 Albumin fusion proteins
12/01/2005US20050266528 Proteolytic blood coagulation factor for treatment and prevention of preclampsia and thrombotic disorders
12/01/2005US20050266526 Glycoprotein synthesis
12/01/2005US20050266519 Methods and compositions for modulating and detecting activin dimer and dimer formation
12/01/2005US20050266515 Glyceraldehyde 3-phosphate dehydrogenase-S (GAPDHS), a glycolytic anzyme expressed only in male germ cells, is a target for male contraception
12/01/2005US20050266511 High throughput sarcomeric assay
12/01/2005US20050266486 Methods for treating obesity by inhibiting expression of obese gene product receptor variant
12/01/2005US20050266484 gene therapy; a sequence which encodes the polypeptide podocin; proteinuria
12/01/2005US20050266465 Interferon-alpha polypeptides and conjugates
12/01/2005US20050266464 C1q family member proteins with altered immunogenicity
12/01/2005US20050266445 Purified mammalian CTLA-8 antigens and related reagents
12/01/2005US20050266431 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
12/01/2005US20050266423 Novel nucleic acids and polypeptides
12/01/2005US20050266421 Claudin polypeptides, polynucleotides, and methods of making and use thereof
12/01/2005US20050266137 Food composition
12/01/2005US20050266099 Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
12/01/2005US20050266093 Nanogene therapy for cell proliferation disorders
12/01/2005US20050266092 Loaded microspheres
12/01/2005US20050266087 Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
12/01/2005US20050266070 Administering composition comprising hydrocodone covalently bound to a peptide; decreasing the bioavailability by intravenous or intranasal administration
12/01/2005US20050266068 Cardiolipin molecules and methods of synthesis
12/01/2005US20050266067 Nanocell drug delivery system
12/01/2005US20050266056 Films comprising a liquid-absorbant inner layer, an antimicrobial material and an impermeable outer layer
12/01/2005US20050266050 Antimicrobial composition and method for use
12/01/2005US20050266046 Novel IGF-1 composition and its use
12/01/2005US20050266040 Medical devices composed of porous metallic materials for delivering biologically active materials
12/01/2005US20050266036 Microbial biosurfactants as agents for controlling pests
12/01/2005US20050266029 with botulinum toxin
12/01/2005US20050266022 Methods and compositions for use in the treatment of filovirus mediated disease conditions
12/01/2005US20050266020 Modular transport systems for molecular substances and production and use thereof
12/01/2005US20050266014 Tumor antigen based on products of the tumor suppressor gene WT1
12/01/2005US20050266013 Diagnosis of RH factor; using polypeptides to form antibodies; purified polypeptide capable of forming antigen binding structures with specificity for Rhesus D antigens for treating idiopathic thrombocytopenic purpura (ITP) or mistransfusion of Rhesus incompatible blood
12/01/2005US20050266006 Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
12/01/2005US20050266002 Methods for the treatment of cancer using anti-CD40 antibodies
12/01/2005US20050265996 Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients
12/01/2005US20050265992 cell adhesion molecule determined to effect platelet aggregation, secretion, platelet spreading and cellular adhesion; thrombosis, atherosclerosis, heart attacks, stroke and other clinical disorders involving thrombus formation
12/01/2005US20050265990 Treatments and nutritional supplements for assisting post-exercise recovery
12/01/2005US20050265989 Non-toxic purification and activation of prothrombin and use thereof
12/01/2005US20050265988 Glycosylated glucocerebrosidase expression in fungal hosts
12/01/2005US20050265987 Sulfatases and methods of use thereof
12/01/2005US20050265986 Sphingomyelinase compositions and use thereof
12/01/2005US20050265985 nucleotide sequences that code serine/threonine protein kinase, used for analyzing or screening breast cancers; gene therapy
12/01/2005US20050265972 A genetic construct containing a glucose inducible regulatory element with a pair of CACGTG nucleotide sequences and confer human proinsulin expression in host hepatocyte cells; therapy for diabetes
12/01/2005US20050265970 Identifying agents which modify mitogen activated kinase activities associated with cell death; small interfering RNA and treament of cell proliferative disorders; for modulating diseases and conditions associated with elevated or decreased apoptosis
12/01/2005US20050265969 Therapeutic chemokine receptor antagonists
12/01/2005US20050265968 Administering interferon-tau to increase blood IL-10 level relative to the level before administering interferon-tau; especially for treating an autoimmune condition.
12/01/2005US20050265967 Interferon-alpha induced gene
12/01/2005US20050265966 Methods of treating cancer using IL-21 and monoclonal antibody therapy
12/01/2005US20050265965 Modified cytokines for use in cancer therapy
12/01/2005US20050265964 Stabilizing agent such as polyhydric alcohol or salt, a buffer , a sugar and polymeric compound for minimizing degradation of multifunctional glycoprotein (leukaemia inhibitory factor), additive to maintain acidic ph and isotonicity, and carriers
12/01/2005US20050265963 Immunodynamic complexes and methods for using and preparing such complexes
12/01/2005US20050265962 selectively inhibiting the activity of wild-type soluble TNF-alpha; reduced side effect profile, including reduced infection rates; use treating autoimmune diseases
12/01/2005US20050265961 Biodegradable poly(beta-amino esters) and uses thereof
12/01/2005US20050265956 Polyalkyleneimine-graft-biodegradable polymers for delivery of bioactive agents
12/01/2005US20050265946 Elastase inhibitor
12/01/2005US20050265932 Collagenolytic active enzyme containing compositions, and their use in the dental field
12/01/2005DE102004023187A1 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie Identifying surface-associated antigens for tumor diagnosis and therapy
12/01/2005CA2607686A1 Use of gelsolin to treat infections
12/01/2005CA2572446A1 Combinatorial selection of phosphorothioate aptamers for tgf-beta
12/01/2005CA2571828A1 Bacterial efflux pump inhibitors and methods of treating bacterial infections
12/01/2005CA2568248A1 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
12/01/2005CA2567496A1 C1q family member proteins with altered immunogenicity
12/01/2005CA2567455A1 Adenovirus/alphavirus hybrid vector for the effective administration and expression of therapeutic genes in tumour cells
12/01/2005CA2567330A1 Methods for treating and diagnosing cancer with wnt inhibitory factor-1 (wif-1)
12/01/2005CA2567314A1 Cartilage and bone repair composition
12/01/2005CA2567297A1 Tissue sealant
12/01/2005CA2566903A1 Modified antigen-presenting cells
12/01/2005CA2566850A1 Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a gst-activated anticancer compound
12/01/2005CA2566848A1 Compositions comprising dkk2 and methods for use thereof for the stimulation or enhancement of bone formation and the self-renewal of cells
12/01/2005CA2566747A1 Topical cromolyn formulations
12/01/2005CA2566745A1 Methods of treating cancer using il-21 and monoclonal antibody therapy
12/01/2005CA2566675A1 Improving bone formation and preservation by surgically inducing an increase in osteoblast activity coupled with the effect of administering a bone anabolic agent
12/01/2005CA2566610A1 Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
12/01/2005CA2566445A1 Methods related to the treatment of neurodegenerative and inflammatory conditions
12/01/2005CA2566439A1 Methods of preventing and treating alimentary mucositis
12/01/2005CA2566363A1 High affinity ny-eso t cell receptor
12/01/2005CA2566333A1 Modulation of immunoglobulin production and atopic disorders
12/01/2005CA2566247A1 Interferon-alpha polypeptides and conjugates
12/01/2005CA2566079A1 Nucleic acid microspheres, production and delivery thereof
12/01/2005CA2566062A1 Treatment or prevention of respiratory viral infections with immunomodulator compounds
12/01/2005CA2566032A1 Apparatus and method for transdermal delivery of parathyroid hormone agents
12/01/2005CA2565974A1 Cell surface receptor isoforms and methods of identifying and using the same
12/01/2005CA2565819A1 Methods of treating disease with random copolymers
12/01/2005CA2565300A1 Fgf-21 fusion proteins
12/01/2005CA2564770A1 Chimeric soluble hyper il-11 and use thereof
12/01/2005CA2564538A1 Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors
12/01/2005CA2564466A1 Method of preparation and use of fibrinolytic enzymes in the treatment of disease
12/01/2005CA2564332A1 Powders containing novel oligosaccharide mixtures and methods for producing the same
12/01/2005CA2563702A1 Probiotic compounds from lactobacillus gg and uses therefor
12/01/2005CA2562990A1 Mucinous glycoprotein (muc-1) vaccine
12/01/2005CA2562701A1 Cross-linked antibodies
12/01/2005CA2557053A1 Stamp2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
11/2005
11/30/2005EP1600511A1 Method of treating ischemic disease
11/30/2005EP1600507A1 Cis-element regulating transcription, transcriptional regulatory factor binding specifically thereto and use of the same
11/30/2005EP1600506A2 Oligoribonucleotides and ribonucleases for cleaving RNA
1 ... 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 ... 3163